Alliant Medical Technologies Announces Receipt of Notice Termination of Production and Distribution Agreements.Business/Technology Editors & Health/Medical Writers NORWOOD, Mass.--(BW HealthWire)--May 10, 2002 UroMed Corporation d/b/a ALLIANT Medical Technologies (OTCBB OTCBB See OTC Bulletin Board (OTCBB). : URMD.OB) announced today that it has received notice of termination from Bebig Isotopen- und Medizintechnik GmbH of its agreement to produce Brachytherapy brachytherapy /brachy·ther·a·py/ (-ther´ah-pe) treatment with ionizing radiation whose source is applied to the surface of the body or within the body a short distance from the area being treated. Seeds for Alliant. Alliant also announced that it has received notice of termination from Isotope Products Laboratories, Inc. of its agreement with Alliant and Bebig to distribute Brachytherapy Seeds on behalf of Alliant. RISK FACTORS Certain risks relevant to the Company's business are described in the Company's Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the year ended December 31, 2001, under the headings "Forward-Looking Statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. and Associated Risks" and "Risk Factors," and are incorporated herein by reference. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion